Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis.
about
Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couplesAntiretroviral therapy for prevention of HIV transmission in HIV-discordant couplesAntiretroviral therapy for prevention of HIV transmission in HIV-discordant couplesTowards combination HIV prevention for injection drug users: addressing addictophobia, apathy and inattentionReview: [corrected] The changing face of the HIV epidemic in sub-Saharan AfricaFactors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010.Antiretroviral prophylaxis for HIV prevention in heterosexual men and womenWhy primate models matter.Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South AfricaState of the science of adherence in pre-exposure prophylaxis and microbicide trials.Pre-exposure prophylaxis state of the science: empirical analogies for research and implementation.Simple epidemiological dynamics explain phylogenetic clustering of HIV from patients with recent infectionA qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infectionImplementation science of pre-exposure prophylaxis: preparing for public use.Optimizing ART adherence: update for HIV treatment and preventionThe HIV/AIDS epidemic in sub-Saharan Africa: thinking ahead on programmatic tasks and related operational research.Preexposure prophylaxis for HIV prevention.Progress in HIV reduction and prevention among injection and noninjection drug users.Update on microbicide research and development - seeking new HIV prevention tools for women.Neurological syndrome in an HIV-prevention trial participant randomized to daily tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, KenyaThe acceptability and feasibility of a brief psychosocial intervention to reduce blood-borne virus risk behaviours among people who inject drugs: a randomised control feasibility trial of a psychosocial intervention (the PROTECT study) versus treatmAntiretroviral nonadherence and condomless sex in the HIV Outpatient Study, USA, 2007-2014.Trends in condom use among MSM in the United States: the role of antiretroviral therapy and seroadaptive strategies.The Role of Structural Barriers in Risky Sexual Behavior, Victimization and Readiness to Change HIV/STI-Related Risk Behavior Among Transgender Women.Demographic Differences in PrEP-Related Stereotypes: Implications for Implementation.Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States.
P2860
Q24197939-1698F729-D162-47B5-8848-1981F04C71B8Q24234597-DBB96501-D052-4648-A3A9-B4FF04B2C054Q24234903-B4364B05-0272-4A13-A662-31FF92E1A4C2Q27008531-71B5FF43-E82B-401D-AEC2-E0539B33581AQ27022927-B8A38D06-5E55-42AA-B083-F92EBA0FF1C8Q27318158-2D553D8A-D2BD-420D-8DB3-6E571DBECB37Q28270788-650E32F8-DCDF-459D-9CF3-D533304BD5ACQ30417520-DFB55607-2B1E-4331-A090-493801E82D72Q33747742-A5399D6A-D07B-4E4B-8CF8-CCD35B9C70FBQ33798685-03896457-741E-40AC-9566-FB612784D83DQ34123592-145AE822-F2F9-4F0B-A68C-9219FD9040CDQ34285912-A1663BFB-5AC1-4E97-89FA-01AF983178B1Q34336592-AEB5894B-F0E3-4CA8-9140-637E4BFE3FA6Q34448430-7E647B9B-7B97-4B29-BD91-93D5F5311E06Q34717901-28FB25A2-EF7B-425B-9A21-86B46E4F1F12Q35357681-95D8B839-AA6B-41D0-A2E6-10E3E1C94420Q35717688-D1B885B0-C59F-401E-82C4-E1849CD3189AQ35816921-3CE078A9-2C78-44E5-9D7E-A88460E39FB9Q35958928-236C7EC2-E294-4D43-B998-AB097BC7240EQ37388369-085CEE02-DCEF-4181-8645-F229315BB103Q37713321-419CB06A-0F1E-4569-BA8F-7E5E06A32DC0Q38669631-EB34553C-CCB3-4DB8-8CA4-8A74A4EE3D6BQ39791811-E916EC86-7C60-410B-BD0E-24CFAB0CFFE3Q40679190-FD46DECE-718A-4FD1-96A2-993A32B9EB2DQ41122508-6F3DB68C-7BD6-4AA1-AB30-180E6A11086DQ49382513-27014B02-31C0-4763-A8FC-B8B8D2087BD5
P2860
Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Antiretroviral agents used by ...... and postexposure prophylaxis.
@en
type
label
Antiretroviral agents used by ...... and postexposure prophylaxis.
@en
prefLabel
Antiretroviral agents used by ...... and postexposure prophylaxis.
@en
P2860
P356
P1476
Antiretroviral agents used by ...... and postexposure prophylaxis.
@en
P2860
P304
P356
10.1086/651479
P407
P478
50 Suppl 3
P577
2010-05-01T00:00:00Z